

REDUCING HOSPITAL READMISSIONS IN HEART FAILURE: PHARMACY'S PIVOTAL ROLE

Thursday, September 14, 2017

12:00pm-1:00pm

Drury Lane Theatre & Conference Center

Crystal Room
100 Drury Lane
Oakbrook Terrace, IL 60181

FACULTY

Michael B. Bottorff, PharmD, FCCP, FNLA, CLS

Professor and Chair
Department of Pharmacy Practice
Manchester College of Pharmacy
Fort Wayne, IN



Medical Learning Institute, Inc.
LEADERS IN MEDICAL ACCREDITATION

This activity is provided by
Medical Learning Institute, Inc.

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation and Relypsa, Inc.,
a Vifor Pharma company.

Held in conjunction with the ICHP Annual Meeting.
For more information please select: http://www.ichpnet.org/events/annual_meeting/

PROGRAM DESCRIPTION

Because of the prevalence and burden of heart failure (HF), the quality of HF management—particularly as it concerns the rate of hospital admission and readmission—has produced an important set of performance metrics. Health-system pharmacists must be cognizant of these metrics, which can affect rankings and earnings system-wide.

The factors outlined above make HF a serious disease with a high patient load, subject to pressure to reduce hospitalization, and characterized by an evolving management paradigm. In other words, HF is a significant and growing responsibility in hospital pharmacy practice. Pharmacists working in integrated healthcare delivery systems play a key role in affecting best practices and resource utilization in HF management. They are also gatekeepers, helping to ensure that facilities meet payer and internal quality measures in HF by appropriate prescribing. Pharmacists also help to evaluate the evidence supporting novel therapies and monitoring systems, so they can directly influence the uptake of innovations in the health system.

This program will address gaps in knowledge and competence regarding HF management in an era of new developments in quality metrics, treatment, biomarker testing, and electronic monitoring.

LEARNING OBJECTIVES

Upon completion of this activity, the participant will be able to:

Pharmacists

- Describe the high incidence and burden of HF, including the risk of hospitalization and the need to meet quality metrics for the reduction of readmissions in HF
- Explain the complex pathophysiology and risk factors for HF
- Integrate new classes of pharmacologic agents for HF into the current effective treatment paradigm
- Plan for the use of biomarkers and novel electronic monitoring technologies to workup, monitor treatment follow-up and medication adjustment in HF

Pharmacy Technicians

- Explain the burden of and challenges faced in reducing hospitalization and readmission in HF
- Describe the types, causes, and signs and symptoms of HF
- Identify new classes of pharmacologic agents for HF
- Recognize new frontiers in workup, monitoring and treatment in HF


PROGRAM AGENDA

- | | |
|------------|--|
| 5 minutes | Introduction and Overview: The challenge of reducing hospitalization and readmission in HF |
| 10 minutes | Epidemiology and health-system burden of HF in the US |
| 10 minutes | Pathophysiology and risk factors of HF |
| 10 minutes | Updating the treatment of HF |
| 15 minutes | New frontiers in workup, monitoring, and treatment of HF |
| 10 minutes | Conclusions and Q&A |

TARGET AUDIENCE

This educational activity is directed toward hospital and health-system pharmacists and pharmacy technicians that manage patients with HF.

PHARMACY CREDIT DESIGNATION



The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this application-based activity provides for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit.

Universal Activity Number: 0468-0000-17-001-L01-P

Universal Activity Number: 0468-0000-17-006-L01-T

INSTRUCTIONS FOR CREDIT

There is no fee for this activity. To receive credit for this CPE activity, please take a few minutes to complete the pre-activity assessment and evaluation form and return it to the on-site coordinator. Your confirmation of reported participation will be e-mailed to you within 4 weeks. You may also choose to complete this evaluation form off-site, return it by mail or fax to:

Medical Learning Institute, Inc.
203 Main Street, Suite 249
Flemington, NJ 08822
609.333.1694 (fax)

For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at 609.333.1693 or ndane@mlicme.org.

For pharmacists and pharmacy technicians, Medical Learning Institute, Inc. will accept your completed evaluation form **up to 30 days following participation** and will report your participation in this educational activity to the NABP ONLY if you provide your NABP e-Profile number and date of birth. Within 6 weeks of participation, you will receive a confirmation email and can then view your participation record at the NABP website: www.mycpemonitor.net.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special need (ie, physical, dietary, etc). Please contact Medical Learning Institute, Inc. prior to the live event at 609.333.1693 x103.